Tackling Cancer Is the Holy Grail: Isomorphic Labs' Demis Hassabis | Bloomberg Tech: Europe 09/12/25

AI-powered drug discovery: is it the next frontier of medicine? From cutting down costs, to speeding up development, the technology promises plenty - but can it deliver? In this episode, Bloomberg's Tom Mackenzie speaks exclusively to Demis Hassabis, the Nobel Laureate aiming to literally "solve all disease" through his work at London-based Isomorphic Labs. Hassabis' work comes in addition to his responsibilities at Alphabet Inc., where he oversees all of the company's core AI work as co-founder and CEO of Google DeepMind. --- "Bloomberg Tech: Europe" spotlights the biggest names and trends shaping the region's technology ecosystem as the global competition heats up. This monthly, 30-minute magazine-style show features in-depth interviews with top technology leaders, as well as major investors and policymakers - giving you a compelling A to Z of the most consequential innovations, opportunities and challenges. Chapters: 00:00:00 - Bloomberg Tech: Europe 00:01:16 - Isomorphic Labs Working To 'Solve All Disease' 00:02:03 - Demis Hassabis, Isomorphic Labs Founder & CEO 00:11:51 - Max Jaderberg, Isomorphic Labs Chief AI Officer 00:15:53 - Rebecca Paul, Isomorphic Labs Medicinal Drug Design Head 00:19:51 - Mihaela van der Schaar, University of Cambridge -------- Like this video? Subscribe to Bloomberg Technology on YouTube:    / @bloombergtechnology     Watch the latest full episodes of "Bloomberg Technology" with Caroline Hyde and Ed Ludlow here:    • "Bloomberg Tech" With Ed Ludlow     Get the latest in tech from Silicon Valley and around the world here: https://www.bloomberg.com/technology Connect with us on... X:   / technology   Facebook:   / bloombergtechnology   Instagram:   / bloombergbusiness     Follow Ed Ludlow on X here:   / edludlow   Follow Caroline Hyde on X here:   / carolinehydetv     Listen to the daily Bloomberg Technology podcast here: https://www.bloomberg.com/podcasts/se...   More from Bloomberg Business Connect with us on... X:   / business   Facebook:   / bloombergbusiness   Instagram:   / bloombergbusiness   LinkedIn:   / bloomberg-news   TikTok:   / bloombergbusiness